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ABSTRACT 
Background and aim: Melissa officinalis was traditionally used for pain relief and treatment of some diseases. The aim of 
the study was to compare the effect of mefenamic acid and Melissa officinalis (Melissa) on pain management in primary 
dysmenorrhea. 
Methods: In this clinical trial, forty- three eligible women with moderate to severe primary dysmenorrhea were randomly 
allocated into the Melissa officinalis and mefenamic acid groups. The mefenamic group received 250 mg capsules every 8 
hours from the onset of menstruation pain until pain relief for three consecutive cycles, and the Melissa group used one tea 
bag in the same manner. The intensity and duration of menstrual pain were assessed by the visual analog scale and a self-
reported questionnaire. Data were analyzed using student t-test, Chi-square and ANOVA. 
Results: The intensity and duration of pain in both groups showed a significant descending trend (In both groups P<0.001); 
however, this trend was greater in Melissa group in terms of pain intensity (P=0.008), with no significant difference on 
pain duration (P=0.101). 
Conclusions: Melissa was more effective than mefenamic acid in relief of pain on primary dysmenorrhea. Regarding to 
safety of Melissa, it could be considered as an alternative treatment for primary dysmenorrhea.  
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INTRODUCTION 
Dysmenorrhea is a gynecological problem with primary 
and secondary forms having overall prevalence between 
16% and 91% in women of reproductive age1,2. 
Primary dysmenorrhea is painful menstruation in absence 
of pelvic pathology3, but abnormal uterine bleeding, 
dyspareunia, non-periodic pain, changes in length and 
duration of pain, and abnormal pelvic examination suggest 
the presence of secondary dysmenorrhea which require 
excessive investigation4. Dysmenorrhea has negative 
effects on women’s quality of life, mood and sleep quality 
during a menstruation cycle with prevalence between 45 
and 95% among menstruating women3. Despite the high 
prevalence of dysmenorrhea, treatment of this problem is 
often ineffective3. Conventional treatment for 
primary dysmenorrhea has a failure rate between 20% and 
25% and may be contraindicated or not tolerated by some 
women5. Non-steroidal anti-inflammatory drugs 
(NSAIDs) are used as the first-line therapy for menstrual 
pain3. Mefenamic acid is a drug of choice for 
dysmenorrhea6. Because of complications due to 
mefenamic acid7, herbal medicines may be a suitable 
alternative5. Nowadays, complementary and alternative 
medicine is a growing area of interest in treatment of 
dysmenorrhea8. Meanwhile, Melissa officinalis L. (Lemon 
balm) belongs to Lamiaceae family have been used 
directly in food or as a decoction or an infusion for 
medicinal purposes9. This herb is native to the eastern 
Mediterranean region and western Asia. Melissa officinalis 
(Lemon balm) is a perennial bushy plant and is upright, 
reaching a height of about one meter. The soft and hairy 
leaves are heart-shaped. Dried or fresh leaves and top 
aerial section of the plant are the parts which are used as 
medicine. The leaves emit a special fragrant lemon odor 
when bruised. The chemical compound of its essential oil 
in different climates is different10. Regarding to the adverse 
effects and insufficient efficacy of NSAIDs and other 
routine pharmacological drugs in alleviation of 
dysmenorrheal and trend of people to herbal drugs, 
replacing these drugs with herbal ones which have less side 
effects can be effective7. On the other hand, the efficacy of 
Melissa officinal on dysmenorrhea was confirmed in a 
previous study in comparison with Salvia officinal11. 
Mefenamic acid is a routine medication for dysmenorrhea; 
therefore, the present study was carried out with the aim of 
comparing the effectiveness of this herb with mefenamic 
acid on primary dysmenorrheal pain.    
 
MATERIALS AND METHODS 
This randomized single-blind clinical trial was conducted 
in gynecology clinic of Hajar Hospital affiliated with 
Shahrekord University of Medical Sciences in April 2012.  
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Table 1: Demographic and Menstruation Characteristics 
of Women in Two Study Groups 
Variable  Mefnamic 
acid group 
Melisa 
Group 
P- 
value 
Age(year) 25.38±7.71 24.55±4.78 0.67 
Duration of 
Menstrual 
Cycles (day) 
6.10±1.17 6.64±0.72 0.07 
Menarche Age 
(year) 
11.52±7.46 11.73±4.54 0.26 
Interval of 
Menstrual 
Cycles (day) 
26.55±3.99 27.73±2.65 0.91 
 
Amongst 138 eligible women with primary dysmenorrhea 
referred to this clinic, 60 women were selected (figure1). 
The participants were randomly allocated into two groups 
of Melissa (n=30) and mefenamic acid (n=30). 
Inclusion criteria were willingness to participate in the 
study, age over than 17 years, suffering from moderate to 
severe primary dysmenorrhea regarding to the initial 
evaluation by Visual Analogues Scale (score more than 3), 
being single, having regular menstrual cycles, and using no 
contraceptives. Exclusion criteria were secondary 
dysmenorrhea, history of pelvic inflammatory diseases, 
vaginal infection, use of oral contraceptive pills (OCP) or 
intrauterine device (IUD), any known gastrointestinal, 
urogenital, hematological or other systemic disorders, 
being under treatment of psychological disorders, 
consumption of any analgesic drugs, and previous history 
of hyper-sensitivity to NSAIDs or Melissa officinalis.  
Ethical considerations 
The study protocol was approved by the ethical Committee 
of Shahrekord University of Medical Sciences with ethical 
code no: 88-10-1 and registered in IRCT by 
IRCT201605292085N17. Integrated explanations about 
the study were given to the participants then, informed 
consent was taken. 
Study Questionnaire 
The pain severity was evaluated by Visual Analogue Scale 
(VAS), which is a standard pain assessment tool. In 
clinical practice, the percentage of pain relief which is 
measured by VAS is considered as a measure of the 
efficacy of treatment12. In this scale, zero indicates "no 
feeling of pain” and 10 "severe pain”13 with a 10-point 
ruler. According to the 10-point VAS, mild dysmenorrhea 
was defined as score of 0-3, moderate as score of 4-7 and 
severe as score of 8-10 (14). Women with mild 
dysmenorrhea (score of 0-3) were excluded from this 
study18. Reliability and validity of VAS have been 
demonstrated in several studies12. In addition, the 
demographic and menstrual condition of participants 
consist of demographic status such as age, educational 
level, menstrual history consist of menarche age, interval 
and duration of menstrual cycles were assessed. 
Intervention 
Women in the mefenamic acid group received mefenamic 
acid capsules 250 mg (Razak Co, Tehran, Iran) from the 
onset of the menstrual period until the third day, every 8 
hours until pain relief for 3 cycles15. The patients in 
Melissa group were administered one tea bag of Melissa 
(Golchai Co, Alborz, Iran) in the same manner, every 8 
hours until pain relief. In present study, all of the diagnosis, 
medication, and follow up stages were under consideration 
of a gynecologist. The researchers followed the 
participants by telephone during the study in view of 
regular taking the medication. The measurement of pain 
intensity and duration were carried out in four stages: at 
the beginning of the study (initial evaluation), and three 
consecutive cycles late. Before administration of drug, 2, 
4, and 6 hours later the pain duration and intensity were 
measured during the first three days of each menstrual 
cycle. The mean of these scores was calculated and 
compared in different cycles within and between two study 
groups. A written instruction was provided in manner of 
drugs consumption method and their probable side effects, 
as well as reporting pain intensity and duration in 
questionnaire. In Melissa group, the patients were 
instructed to put a tea bag in a cup of hot water then wait 
for 5 minutes, remove the bag after squeezing and drink. 
Statistical analysis was carried out using SPSS software 
(version 20, IBM Software, Chicago, Illinois). ANOVA 
and post hoc test using the Bonferroni correction, student 
t-test, and Chi square test were used to compare groups 
between different stages of measurement and demographic 
characteristics. The P value less than 0.05 was considered 
statistically significant. 
 
RESULT 
At the end of the study, in mefenamic acid group 21 and in 
Melissa group 22 women completed the study (in each 
group 9 women were excluded due to the irregular use of 
drug and loss of follow up). Regarding to Kolmogorov-
Smirnov test, the distribution of data in terms of pain 
intensity and duration was normal (P> 0.05). Moreover, 
there was no significant difference between participants in 
two study groups in terms of demographic and menstrual 
characteristics such as age, interval and duration of 
menstrual cycles and menarche age (Table 1). Moreover, 
the majority of participants in both groups had academic 
education (16 in Melissa groupvs.13 in mefenamic acid 
group, P=0.526). In order to compare the changes of pain 
intensity and duration in two groups in specific times, 
ANOVA and student t-test were used. Student t- test 
showed that both groups were matched in terms of pain 
intensity and its duration at the beginning of the study (P= 
0.181 and P= 0.221 respectively). Table 2 shows the 
condition of pain intensity and duration in different 
measurement stages among the patients in both study 
groups. Besides, it showed that the Mauchly test of 
Sphericity for pain intensity was insignificant (P =0.181). 
regarding to the Sphericity assumption, it was indicated a 
significant descending trend in both study groups F (3, 
123) = 29.44, p< 0.001. On the other hand, test between 
subject effect showed a significant difference between the 
study groups in terms of pain intensity in four cycles (F= 
7.67, P= 0.008). It can be concluded that the mefenamic 
acid capsule and Melissa tea bag has been able to decrease 
the pain intensity over a period of three cycles as compared 
to baseline but Melissa group experienced less pain than  
Faranak et al. / The Effect of… 
 
                 IJPPR, Volume 8, Issue 8: August 2016 Page 1288 
mefenamic acid group. In addition, post hoc test using the  
 Bonferroni correction revealed a decline in the value of 
pain intensity at all assessment stages.  Findings showed 
that the pain intensity between the first and third (P 
<0.001), first and forth (P<0.001), second and third 
(P=0.003) and second and forth stages (P<0.001) had a 
significant difference, even though, this difference 
between other stages of assessment were insignificant 
(P>0.05) (figure 2). The results of ANOVA showed that 
the Mauchly test of Sphericity for pain duration is 
significant (P <0.001), which indicates that these data 
violate the Sphericity assumption of the univariate 
approach to ANOVA. Therefore, degree of freedom were 
corrected using Greenhouse-Geisser correction estimates 
of sphericity (eta = 0.694). A repeated measure ANOVA, 
with Greenhouse-Geisser correction, was conducted to  
Table 2: The Pain Intensity and Duration amongst Women in Both Study Groups in Four Stages of Measurement 
 Stage of Measurement  Group Mean SD 
Pain Intensity   Beginning of the Study (The First Cycle) Melissa 5.61 1.125 
Mefenamic 6.13 1.380 
The Second Cycle Melissa 4.697 1.462 
Mefenamic 5.714 1.820 
The Third Cycle Melissa 3.818 1.324 
Mefenamic 4.523 1.536 
The Fourth Cycle Melissa 3.166 .632 
Mefenamic 4.095 1.700 
Pain 
Duration  
Beginning of the Study (The First Cycle) Melissa 85.39 51.536 
Mefenamic 110.24 77.629 
The Second Cycle Melissa 51.3641 24.594 
Mefenamic 81.0476 80.143 
The Third Cycle Melissa 28.8641 11.072 
Mefenamic 52.8571 56.646 
The Fourth Cycle Melissa 24.7732 12.464 
Mefenamic 30.2381 50.011 
 
 
Figure 1: flow chart of Study participants 
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 assess whether there were differences between the average 
duration of pain in four menstrual cycles. Results indicated 
a significant difference, F (2.082, 85.36) = 31.226, p< 
0.001. On the other hand, test between subject effect 
showed an insignificant difference between the study 
groups in terms of pain duration in four cycles (p= 0.101). 
It can be concluded that the mefenamic acid capsule and 
Melissa tea bag has similar effects on decrease the pain 
duration over a period of three cycles as compared to 
baseline. Post hoc test using the Bonferroni correction 
revealed a significant decrease in the value of pain duration 
at all assessment stages (table 3, figure 3). 
 
DISCUSSION 
This study compared the effect of mefenamic acid and 
Melissa officinalis on primary dysmenorrhea. Regarding to 
results of the study, both mefenamic acid capsule and 
Melissa tea bag were able to decrease the pain intensity 
over a period but patients in Melissa group experienced 
less pain than mefenamic acid group. On the other hand, 
 
Figure 2: Trends of Pain Intensity among Study Groups 
 
 
Figure 3: Trends of Pain duration among study Groups 
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duration of pain in menstrual cycles had a similar 
descending trend in both group. Many studies have 
investigated treatment of dysmenorrheal pain. However, 
the analgesic effect of mefenamic acid remains relevant for 
some gynecological disorders, although considerable 
competition from other NSAIDs16 and different studies 
showed the efficacy of this drug in dysmenorrheal7,17,18. 
NSAIDs decrease the menstrual pain by decreasing 
intrauterine pressure and lowering prostaglandin F2 levels 
in menstrual fluid19-21. The effectiveness of herbal 
medicines in primary dysmenorrhea has been 
demonstrated in different studies. Park et al, in a review 
study concluded that effectiveness of herbal medicines on 
primary dysmenorrhea is associated to inhibition of uterine 
contractions and their peripheral analgesic and anti-
inflammatory activities via the inhibition of prostaglandin 
synthesis. Decrease in prostaglandin level, suppression of 
cyclooxygenase-2 expression, superoxide dismutase 
activation and malondialdehyde (MDA) reduction, 
stimulation of somatostatin receptor, intracellular Ca2+ 
reduction, and recovery of phospholipid metabolism are 
some of the probable mechanism involved in primary 
dysmenorrhea22. Phenolic component of plant especially 
Rosmarinic Acid (RA) is responsible for most of the 
activities of Melissa23,24. Melissa has been used 
traditionally as aromatic, digestive, antispasmodic, 
sedative effects23, tonic, carminative, diaphoretic, surgical 
dressing, strengthening the memory, and headache relief , 
but in new pharmacology is effective in the management 
of mild to moderate Alzheimer’s, migraine, and 
rheumatism(10). Also Melissa officinalis contained Nerol 
(30.44%), Citral (27.03%), Isopulegol (22.02%), 
Caryophyllene (2.29%), Caryophyllene oxide (1.24%), 
and Citronella (1.06%) and the essential oil of Melissa 
possesses potential anti-inflammatory activities, 
supporting the traditional use of this plant in treating 
different diseases associated with inflammation and pain25. 
Antinociceptive effect of Melissa was demonstrated in 
previous studies. Guginski G suggested that the extract of 
Melissa produced dose-related antinociception in several 
models of chemical pain 
through mechanisms that involved cholinergic systems 
through muscarinic and nicotinic acetylcholine receptors 
and the L-arginine-nitric oxide pathway. In addition, the 
rosmarinic acid in this plant appears to contribute for the 
antinociceptive property of the extract26. In study of 
Boonyarikpunchai et al. rosmarinic acid showed a 
significant activity against PGE2-induced paw edema by 
central and peripheral anti-nociceptive activities and 
has anti-inflammatory effects against acute and chronic 
inflammation27. Lipid peroxidation and oxidative stress 
have a significant role in the pathogenesis of primary 
dysmenorrheal. Dikensoy  et al,. found that the serum 
levels of MDA and nitric oxide (NO) increase in subjects 
with primary dysmenorrheal28. Flavonoids in Melissa 
directly interact in the synthesis of prostaglandins29. Sadri 
et al, in their study demonstrated the inhibitory effects of 
Melissa on contraction of rat ileum30. As it was mentioned 
dysmenorrhea is associated with oxidative stress and 
Melisa has high antioxidant activity. Therefore, 
antioxidant activity of this plant might be responsible for a 
part of its effect. Antioxidants are involved in variety of 
diseases such as neurologic disorders31,32 
ischemia/reperfusion33,34, diabetes35,36, athrosclerosis37,38, 
cardiovascular diseases39,40 and wound complication41,42. 
These conditions involve many changes, including 
alterations in redox state43,44. Therefore, Melissa 
possessing high antioxidant activity may also be effective 
in these conditions. 
 
CONCLUSION 
According to findings of the present study, Melissa is as 
effective as mefenamic acid in pain relief on primary 
dysmenorrhea. Melissa is a safe medical plant which could 
be recognized as an alternative treatment for primary 
dysmenorrhea. However, the exact underlying mechanism 
of Melissa on dysmenorrheal pain is not clear and this herb 
have different ingredient which could be associated to its 
anti-nociceptive effects. 
Limitation 
The small sample size and short term follow up period are 
the limitation of this study.  
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